{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T15:09:22Z","timestamp":1768748962010,"version":"3.49.0"},"reference-count":18,"publisher":"Canadian Science Publishing","issue":"5","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.nrcresearchpress.com\/page\/about\/CorporateTextAndDataMining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can. J. Physiol. Pharmacol."],"published-print":{"date-parts":[[2007,5]]},"abstract":"<jats:p> The radial artery (RA) is used as a spastic coronary bypass graft. This study was designed to investigate the mechanism of vasorelaxant effects of YC-1 (3-(5\u2032-hydroxymethyl-2\u2032-furyl)-1-benzyl indazole), a nitric oxide (NO)-independent soluble guanylate cyclase (sGC) activator, and DEA\/NO (diethylamine\/nitric oxide), a NO-nucleophile adduct, on the human RA. RA segments (n = 25) were obtained from coronary artery bypass grafting patients and were divided into 3\u20134\u00a0mm vascular rings.Using the isolated tissue bath technique, the endothelium-independent vasodilatation function was tested in vitro by the addition of cumulative concentrations of YC-1 (10<jats:sup>\u221210<\/jats:sup> to 3\u00a0\u00d7 10<jats:sup>\u22127<\/jats:sup>\u00a0mol\/L) and DEA\/NO (10<jats:sup>\u22128<\/jats:sup> to 3\u00a0\u00d7 10<jats:sup>\u22125<\/jats:sup>\u00a0mol\/L) following vasocontraction by phenylephrine in the presence or absence of 10<jats:sup>\u22125<\/jats:sup>\u00a0mol\/L ODQ (1H-(1,2,4)oxadiazole(4,3-a)quinoxalin-1-one), the selective sGC inhibitor, 10<jats:sup>\u22127<\/jats:sup>\u00a0mol\/L iberiotoxin, a blocker of Ca<jats:sup>2+<\/jats:sup>-activated K<jats:sup>+<\/jats:sup> channels, or 10<jats:sup>\u22125<\/jats:sup>\u00a0mol\/L ODQ plus 10<jats:sup>\u22127<\/jats:sup>\u00a0mol\/L iberiotoxin. We also evaluated the effect of YC-1 and DEA\/NO on the cGMP levels in vascular rings obtained from human radial artery (n = 6 for each drug). YC-1 (10<jats:sup>\u221210<\/jats:sup> to 3\u00a0\u00d7 10<jats:sup>\u22127<\/jats:sup>\u00a0mol\/L) and DEA\/NO (10<jats:sup>\u22128<\/jats:sup> to 3\u00a0\u00d7 10<jats:sup>\u22125<\/jats:sup>\u00a0mol\/L) caused the concentration-dependent vasorelaxation in RA rings precontracted with phenylephrine (10<jats:sup>\u22125<\/jats:sup>\u00a0mol\/L) (n = 20 for each drug). Pre-incubation of RA rings with ODQ, iberiotoxin, or ODQ plus iberiotoxin significantly inhibited the vasorelaxant effect of YC-1, but the inhibitor effect of ODQ plus iberiotoxin was significantly more than that of ODQ and iberiotoxin alone (p\u00a0&lt; 0.05). The vasorelaxant effect of DEA\/NO almost completely abolished in the presence of ODQ and iberiotoxin plus ODQ, but did not significantly change in the presence of iberiotoxin alone (p\u00a0&gt; 0.05). The pEC<jats:sub>50<\/jats:sub> value of DEA\/NO was significantly lower than those for YC-1 (p\u00a0&lt; 0.01), with no change E<jats:sub>max<\/jats:sub> values in RA rings. In addition, YC-1-stimulated RA rings showed more elevation in cGMP than that of DEA\/NO (p\u00a0&lt; 0.05). These findings indicate that YC-1 is a more potent relaxant than DEA\/NO in the human RA. The relaxant effects of YC-1 could be due to the stimulation of the sGC and Ca<jats:sup>2+<\/jats:sup>-sensitive K<jats:sup>+<\/jats:sup>channels, whereas the relaxant effects of DEA\/NO could be completely due to the stimulation of the sGC. YC-1 and DEA\/NO may be effective as vasodilator for the short-term treatment of perioperative spasm of coronary bypass grafts. <\/jats:p>","DOI":"10.1139\/y07-033","type":"journal-article","created":{"date-parts":[[2007,7,19]],"date-time":"2007-07-19T18:21:20Z","timestamp":1184869280000},"page":"521-526","source":"Crossref","is-referenced-by-count":7,"title":["Investigation of the vasorelaxant effects of 3-(5\u2032-hydroxymethyl-2\u2032-furyl)-1-benzyl indazole (YC-1) and diethylamine\/nitric oxide (DEA\/NO) on the human radial artery used as coronary bypass graft"],"prefix":"10.1139","volume":"85","author":[{"given":"Ocal","family":"Berkan","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Surgery, Cumhuriyet University School of Medicine, 58140 Sivas, Turkey."},{"name":"Department of Pharmacology, Cumhuriyet University School of Medicine, 58140 Sivas, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ihsan","family":"Bagcivan","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Cumhuriyet University School of Medicine, 58140 Sivas, Turkey."},{"name":"Department of Pharmacology, Cumhuriyet University School of Medicine, 58140 Sivas, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tijen","family":"Kaya","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Cumhuriyet University School of Medicine, 58140 Sivas, Turkey."},{"name":"Department of Pharmacology, Cumhuriyet University School of Medicine, 58140 Sivas, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kemal","family":"Yildirim","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Cumhuriyet University School of Medicine, 58140 Sivas, Turkey."},{"name":"Department of Pharmacology, Cumhuriyet University School of Medicine, 58140 Sivas, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahin","family":"Yildirim","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Cumhuriyet University School of Medicine, 58140 Sivas, Turkey."},{"name":"Department of Pharmacology, Cumhuriyet University School of Medicine, 58140 Sivas, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kas\u0131m","family":"Do\u011fan","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Cumhuriyet University School of Medicine, 58140 Sivas, Turkey."},{"name":"Department of Pharmacology, Cumhuriyet University School of Medicine, 58140 Sivas, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"155","reference":[{"key":"atypb1\/ref1","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/0003-4975(92)91007-V","volume":"54","author":"Acar C.","year":"1992","journal-title":"Ann. Thorac. Surg."},{"key":"atypb2\/ref2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0003-4975(10)65825-0","volume":"16","author":"Carpentier A.","year":"1973","journal-title":"Ann. Thorac. Surg."},{"key":"atypb3\/ref3","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.94.19"},{"key":"atypb4\/ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5223(03)00388-X"},{"key":"atypb5\/ref5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1124\/mol.53.1.123","volume":"53","author":"Friebe A.","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"atypb6\/ref6","doi-asserted-by":"publisher","DOI":"10.1067\/mtc.2001.113593"},{"key":"atypb7\/ref7","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00969.x"},{"key":"atypb8\/ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)02730-9"},{"key":"atypb9\/ref9","doi-asserted-by":"publisher","DOI":"10.1016\/1053-0770(91)90099-F"},{"key":"atypb10\/ref10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BFb0033669","volume":"135","author":"Koesling D.","year":"1999","journal-title":"Rev. Physiol. Biochem. Pharmacol."},{"key":"atypb11\/ref11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.190333697"},{"key":"atypb12\/ref12","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00005344-199300221-00003","volume":"22","author":"Morley D.","year":"1993","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"atypb13\/ref13","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000126286.47618.BD"},{"key":"atypb14\/ref14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3900843"},{"key":"atypb15\/ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(98)01299-5"},{"key":"atypb16\/ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-3623(98)00087-1"},{"key":"atypb17\/ref17","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1124\/mol.59.2.220","volume":"59","author":"Schmidt K.","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"atypb18\/ref18","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1161\/01.HYP.13.6.658","volume":"13","author":"Vanhoutte P.M.","year":"1989","journal-title":"Hypertension"}],"container-title":["Canadian Journal of Physiology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nrcresearchpress.com\/doi\/full-xml\/10.1139\/Y07-033","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nrcresearchpress.com\/doi\/pdf\/10.1139\/Y07-033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T03:47:55Z","timestamp":1578282475000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nrcresearchpress.com\/doi\/10.1139\/Y07-033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["10.1139\/Y07-033"],"URL":"https:\/\/doi.org\/10.1139\/y07-033","relation":{},"ISSN":["0008-4212","1205-7541"],"issn-type":[{"value":"0008-4212","type":"print"},{"value":"1205-7541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}